Brief: Schrödinger Discontinues Development Of Sgr-2921 Cdc7 Inhibitor
14/08/2025 13:05
Aug 14 (Reuters) - Schrodinger Inc SDGR.O: SCHRODINGER INC - SCHRÖDINGER DISCONTINUES DEVELOPMENT OF SGR-2921 CDC7 INHIBITOR SCHRODINGER INC - SCHRÖDINGER HALTS SGR-2921 AFTER TWO TREATMENT-RELATED DEATHS Source text: ID:nBw7RP93wa Further company coverage: SDGR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Schrodinger
See all newsBrief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Schrodinger Inc reports results for the quarter ended June 30 - Earnings Summary
Schrodinger Q2 revenue beats estimates, swings to profit
Brief: Schrodinger Q2 Revenue USD 58.889 Million Vs. IBES Estimate USD 47.2 Million
Brief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)